Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
November 15 2021 - 4:01PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that it
plans to report its financial results for its fiscal fourth quarter
and year-ended September 30, 2021 after the U.S. market closes on
November 22, 2021. Enanta management will host a conference call at
4:30 p.m. ET to discuss these results and provide an update on
Enanta’s business, including its research and development
pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial
844-467-7101 in the U.S. or 270-215-9353 for international callers.
A replay of the conference call will be available starting at
approximately 7:30 p.m. ET on November 22, 2021, through 11:59 p.m.
ET on November 29, 2021 by dialing 855-859-2056 from the U.S. or
404-537-3406 for international callers. The passcode for both the
live call and the replay is 1973737. A live audio webcast of the
call and replay can be accessed by visiting the “Events and
Presentations” section on the “Investors” page of Enanta’s website
at www.enanta.com.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates currently in development
for the following disease targets: respiratory syncytial virus
(RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is
also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211115006204/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024